Regulus Therapeutics (RGLS) Reports In-Line Q4 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.07), in-line with the analyst estimate of ($0.07).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• MSCI acquires First Street for $120M to expand climate risk data